Download PDF
Thromb Haemost 1977; 37(03): 471-476
DOI: 10.1055/s-0038-1649257
Original Article
Schattauer GmbH

Characterisation of Serum Fibrinogen Degradation Products Using Gel Chromatography and Radioimmunoassay

S. M Ratky
1   Department of Reproductive Physiology, St. Bartholomew’s Hospital Medical College and the London Hospital Medical College, London
,
A Sykes
1   Department of Reproductive Physiology, St. Bartholomew’s Hospital Medical College and the London Hospital Medical College, London
,
E. D Cooke
1   Department of Reproductive Physiology, St. Bartholomew’s Hospital Medical College and the London Hospital Medical College, London
*   Postgraduate Medical Centre, Hackney Hospital, London
,
Y. B Gordon
1   Department of Reproductive Physiology, St. Bartholomew’s Hospital Medical College and the London Hospital Medical College, London
› Author Affiliations
Further Information

Publication History

Received 14 August 1976

Accepted 03 March 1977

Publication Date:
03 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Fibrin(ogen) degradation products (FDP) are detected by radioimmunoassay in the serum of all subjects. Some of these FDPs have considerable biological activity in vivo, and hence may play a significant part in the process of coagulation. Chromatography of serum samples from patients including those with pulmonary emboli and deep venous thrombosis indicates that the majority of non-clottable fibrin(ogen)-related antigen present is of high molecular weight- greater than that of fibrinogen – and that in pathological situations there is a quantitative increase not a qualitative alteration in the molecular species present.

 

  • References

  • 1 Butler M. J, Gordon Y. B, Irving M. H, Sola G. M, Chard T. Serum levels of fibrin(ogen) degradation fragment E antigen in the diagnosis of deep vein thrombosis after abdominal and inguinal surgery. Thrombosis Research 1976; 8: 167
    CrossrefPubMedGoogle Scholar
  • 2 Gatanzaro A, Edgington T. S. The in vivo behaviour of the terminal derivatives of fibrinogen and fibrin cleaved by plasmin. Journal of Laboratory and Clinical Medicine 1974; 83: 458
    PubMedGoogle Scholar
  • 3 Cooke E. D, Bowcock S. A, Pilcher M. F, Ibbotson R. M, Gordon Y. B, Sola C. M, Chard T, Ainsworth M. E. Serum fibrin(ogen) degradation products in the diagnosis of deep vein thrombosis and pulmonary embolism after hip surgery. Lancet II 1975; 51
    PubMedGoogle Scholar
  • 4 Divall G. Studies in fibrinogen/fibrin degradation products as an aid in the identification of blood stains in forensic science. Ph. D. Thesis. University of London.; 1974
    Google Scholar
  • 5 Ferreira H. C, Murat L. G. Fibrina liuve em circulacao. Teste immunologico para iden-tificacao da fibrino liuve. Revista Paulista de Medicina 1961; 59: 103
    PubMedGoogle Scholar
  • 6 Fletcher A. P, Alkjaersig N. Laboratory Diagnosis of Intravascular Coagulation. In: Poller, L. (Ed.) Recent Advances in Thrombosis. Churchill Livingstone; Edinburgh and London: 1973: 87
    Google Scholar
  • 7 Gaffney P. J, Chesterman C. N, Allington M. J. Plasma fibrinogen and its fragments during Streptokinase treatment. British Journal of Haematology 1974; 26: 285
    CrossrefPubMedGoogle Scholar
  • 8 Gordon Y. B, McNeile A. T, Martin M. J, Chard T. Specific and sensitive determination of fibrinogen-degradation products by radioimmunoassay. Lancet 1973; II: 1168
    PubMedGoogle Scholar
  • 9 Gordon Y. B, Martin M. J, Landon J, Chard T. The development of radioimmunoassays for fibrinogen degradation products: fragments D and E. The British Journal of Haematology 1975; a 29: 87
    PubMedGoogle Scholar
  • 10 Gordon Y. B, Ratky S. M, Sola C. M, Lewis J, Baker L. R. I, Chard T. Circulating levels of fibrin/fibrinogen degradation fragment E in normal pregnancy and in association with intrauterine growth retardation and perinatal asphyxia. British Journal of Obstretrics and Gynaecology 1975; b 82: 958
    PubMedGoogle Scholar
  • 11 Gordon Y. B, Cooke E. D, Bowcock S. A, Ratky S. M, Pilcher M. F, Chard T. Noninvasive screening for venous thromboembolic disease. British Journal of Haematology 1977; 35: 505
    CrossrefPubMedGoogle Scholar
  • 12 Larrieu M. J, Dray L, Ardaillou N. Biological effects of fibrinogen-fibrin degradation products. Thrombosis Diathesis Haemorrhagica (Stuttg.) 1975; 34: 686
    PubMedGoogle Scholar
  • 13 Marder V. J, Schulman N. R. High molecular weight derivatives of human fibrinogen produced in plasmin. II Mechanism of their anticoagulant activity. Journal of Biological Chemistry 1969; 244: 2120
    PubMedGoogle Scholar
  • 14 Martin M. J, Gordon Y. B, Ratky S. M, Baker L. R. I, Chard T. Conditions for the collection of serum samples for the measurement of fibrin(ogen) degradation products by radioimmunoassay of Fragment E. Journal of Clinical Pathology 1976; 29: 336
    CrossrefPubMedGoogle Scholar
  • 15 Mossesson M. W, Finlayson J. S, Umfleet R. A, Galanakis D. Human fibrinogen heterogeneities I Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates. Journal of Biological Chemistry 1972; 247: 5210
    PubMedGoogle Scholar
  • 16 Ratky S. M, Martin M. J, Gordon Y. B, Baker L. R. I, Leslie J, Chard T. A comparison between radioimmunossay and other immunological techniques for the measurement of fi-brinogen/fibrin degradation products in serum. British Journal of Haematology 1975; 30: 147
    PubMedGoogle Scholar
  • 17 Vermylen J, Donati M. B, Verstraete M. The identification of fibrinogen derivatives in plasma and serum by agarose gel filtration. Scandinavian Journal of Haematology, Suppl 1971; 13: 219
    PubMedGoogle Scholar